Format
Sort by
Items per page

Send to

Choose Destination

Best matches for OXYCODONE/TU:

Oxycodone/Naloxone prolonged-release: a review of its use in the management of chronic pain while counteracting opioid-induced constipation. Burness CB et al. Drugs. (2014)

Oxycodone for neuropathic pain and fibromyalgia in adults. Gaskell H et al. Cochrane Database Syst Rev. (2014)

Oxycodone for the treatment of postoperative pain. Kokki H et al. Expert Opin Pharmacother. (2012)

Search results

Items: 1 to 20 of 1539

1.

Gallstone Patients with Enhanced Oxidative Stress Biomarker Superoxide Dismutase (SOD1) Plasma Levels Have Significantly Lower Number of Postoperative Analgesic Oxycodone Doses: A Prospective Study with Special Reference to Cancer Patients.

Kärkkäinen J, Saimanen I, Selander T, Aspinen S, Harju J, Juvonen P, Eskelinen M.

Anticancer Res. 2018 Jun;38(6):3573-3578. doi: 10.21873/anticanres.12630.

PMID:
29848712
3.

Oxycodone/naloxone in postoperative pain management of surgical patients.

Gkegkes ID, Minis EE, Iavazzo C.

J Opioid Manag. 2018 Jan/Feb;14(1):52-60. doi: 10.5055/jom.2018.0429. Review.

PMID:
29508896
4.

A prospective, randomized, open label, controlled study investigating the efficiency and safety of 3 different methods of rectus sheath block analgesia following midline laparotomy.

Purdy M, Kinnunen M, Kokki M, Anttila M, Eskelinen M, Hautajärvi H, Lehtonen M, Kokki H.

Medicine (Baltimore). 2018 Feb;97(7):e9968. doi: 10.1097/MD.0000000000009968.

5.

Effect of oxycodone hydrochloride combined with flurbiprofen axetil for intravenous patient-controlled analgesia in lower abdominal patients: A randomized trial.

Xiang X, Yuan X, Lian Y, Fang J, Wu Y.

Medicine (Baltimore). 2018 Feb;97(7):e9911. doi: 10.1097/MD.0000000000009911.

6.

Intranasal abuse potential of an abuse-deterrent oxycodone formulation compared to oxycodone immediate release and placebo in nondependent, recreational opioid users.

Setnik B, Schoedel K, Bartlett C, Dick C, Hakim N, Geoffroy P.

J Opioid Manag. 2017 Nov/Dec;13(6):449-464. doi: 10.5055/jom.2017.0421.

PMID:
29308591
7.

Abuse of reformulated OxyContin: Updated findings from a sentinel surveillance sample of individuals assessed for substance use disorder.

Cassidy TA, Thorley E, Black RA, DeVeaugh-Geiss A, Butler SF, Coplan P.

J Opioid Manag. 2017 Nov/Dec;13(6):425-440. doi: 10.5055/jom.2017.0419.

PMID:
29308589
8.

Utility of Retrograde Amnesia Assessment Alone, Compared with Anterograde Amnesia Assessment in Determining Recovery After Traumatic Brain Injury: Prospective Cohort Study.

Marshman LAG, Hennessy M, Delle Baite L, Britton G.

World Neurosurg. 2018 Feb;110:e830-e834. doi: 10.1016/j.wneu.2017.11.131. Epub 2017 Nov 28.

PMID:
29191531
9.

Oxycodone Ingestion Patterns in Acute Fracture Pain With Digital Pills.

Chai PR, Carreiro S, Innes BJ, Chapman B, Schreiber KL, Edwards RR, Carrico AW, Boyer EW.

Anesth Analg. 2017 Dec;125(6):2105-2112. doi: 10.1213/ANE.0000000000002574.

PMID:
29189367
10.

Effect of a Single Dose of Oral Opioid and Nonopioid Analgesics on Acute Extremity Pain in the Emergency Department: A Randomized Clinical Trial.

Chang AK, Bijur PE, Esses D, Barnaby DP, Baer J.

JAMA. 2017 Nov 7;318(17):1661-1667. doi: 10.1001/jama.2017.16190.

11.

Oxycodone/Naloxone Prolonged Release: A Review in Severe Chronic Pain.

Kim ES.

Clin Drug Investig. 2017 Dec;37(12):1191-1201. doi: 10.1007/s40261-017-0593-1. Review.

PMID:
29098567
12.

Oxycodone Resistance Due to Rifampin Use in an Osteosarcoma Patient with Tuberculosis.

Sakamoto A, Yamashita M, Hori Y, Okamoto T, Shimizu A, Matsuda S.

Am J Case Rep. 2017 Oct 24;18:1130-1134.

13.

Patient-reported health-related quality of life, work productivity, and activity impairment during treatment with ALO-02 (extended-release oxycodone and sequestered naltrexone) for moderate-to-severe chronic low back pain.

Weil AJ, Masters ET, Barsdorf AI, Bass A, Pixton G, Wilson JG, Wolfram G.

Health Qual Life Outcomes. 2017 Oct 17;15(1):202. doi: 10.1186/s12955-017-0749-y.

14.

Prolonged-Release Oxycodone/Naloxone Improves Anal Sphincter Relaxation Compared to Oxycodone Plus Macrogol 3350.

Poulsen JL, Brock C, Grønlund D, Liao D, Gregersen H, Krogh K, Drewes AM.

Dig Dis Sci. 2017 Nov;62(11):3156-3166. doi: 10.1007/s10620-017-4784-7. Epub 2017 Oct 6.

PMID:
28986667
15.

Selection of opioids for cancer-related pain using a biomarker: a randomized, multi-institutional, open-label trial (RELIEF study).

Matsuoka H, Tsurutani J, Chiba Y, Fujita Y, Terashima M, Yoshida T, Sakai K, Otake Y, Koyama A, Nishio K, Nakagawa K.

BMC Cancer. 2017 Oct 6;17(1):674. doi: 10.1186/s12885-017-3664-z.

16.

Transumbilical versus lateral transabdominal removal of benign adnexal masses in laparoscopic surgery-A randomized trial.

Kilpiö O, Härkki PSM, Mentula MJ, Jokela RM, Pakarinen PI.

Eur J Obstet Gynecol Reprod Biol. 2017 Nov;218:49-54. doi: 10.1016/j.ejogrb.2017.08.040. Epub 2017 Sep 4.

PMID:
28950190
17.

In Vitro Drug Release After Crushing: Evaluation of Xtampza® ER and Other ER Opioid Formulations.

Mayock SP, Saim S, Fleming AB.

Clin Drug Investig. 2017 Dec;37(12):1117-1124. doi: 10.1007/s40261-017-0561-9. Erratum in: Clin Drug Investig. 2017 Dec;37(12 ):1203.

18.

Bioavailability of oxycodone after administration of a new prolonged-release once-daily tablet formulation in healthy subjects, in comparison to an established twice-daily tablet
.

Scheidel B, Maritz MA, Gschwind YJ, Steigerwald K, Guth V, Kovacs P, Rey H.

Int J Clin Pharmacol Ther. 2017 Nov;55(11):881-890. doi: 10.5414/CP203005.

19.

Identification of Circulating miRNAs Differentially Regulated by Opioid Treatment.

Toyama K, Kiyosawa N, Watanabe K, Ishizuka H.

Int J Mol Sci. 2017 Sep 16;18(9). pii: E1991. doi: 10.3390/ijms18091991.

20.

Efficacy and safety of controlled-release oxycodone/naloxone versus controlled-release oxycodone in Korean patients with cancer-related pain: a randomized controlled trial.

Lee KH, Kim TW, Kang JH, Kim JS, Ahn JS, Kim SY, Yun HJ, Eum YJ, Koh SA, Kim MK, Hong YS, Kim JE, Lee GW.

Chin J Cancer. 2017 Sep 11;36(1):74. doi: 10.1186/s40880-017-0241-4.

Supplemental Content

Loading ...
Support Center